Prognostication in Uveal Melanoma Using Artificial Intelligence
Disclosure Date:
12/05/2018
Description:
Unmet Need
Uveal melanoma is the most common primary intraocular malignancy in adults. According to the University of Michigan W. K. Kellogg Eye Center, there are 5 to 6 uveal melanoma cases per million people per year. For people over the age of 50, incidence rates increase to 21 cases per million per year. Providing an accurate prognosis for a patient with uveal melanoma is key to identifying the proper corresponding care. Currently, a prognosis can be made after a fine needle biopsy of the melanoma is sent for a gene expression profile (GEP) test. However, the current gold standard for establishing prognosis has its drawbacks. First, the GEP test is only available in the United States and could cost thousands of dollars. Second, a small portion of GEP class 1 patients could still have unexpected poor outcomes.
Technology Overview
Johns Hopkins researchers have developed a novel survival prediction tool that utilizes deep-learning-based image analysis.
Stage of Development
Computational process in development.
Publications
N/A
